449 related articles for article (PubMed ID: 32117582)
1. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis.
Steen EH; Wang X; Balaji S; Butte MJ; Bollyky PL; Keswani SG
Adv Wound Care (New Rochelle); 2020 Apr; 9(4):184-198. PubMed ID: 32117582
[No Abstract] [Full Text] [Related]
2. Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung.
Vermeulen Z; Hervent AS; Dugaucquier L; Vandekerckhove L; Rombouts M; Beyens M; Schrijvers DM; De Meyer GRY; Maudsley S; De Keulenaer GW; Segers VFM
Am J Physiol Heart Circ Physiol; 2017 Nov; 313(5):H934-H945. PubMed ID: 28822966
[TBL] [Abstract][Full Text] [Related]
3. The immunomodulatory role of interleukin-35 in fibrotic diseases.
Luo M; Peng H; Chen P; Zhou Y
Expert Rev Clin Immunol; 2019 Apr; 15(4):431-439. PubMed ID: 30590954
[TBL] [Abstract][Full Text] [Related]
4. Hiding in Plain Sight: Interleukin-11 Emerges as a Master Regulator of Fibrosis, Tissue Integrity, and Stromal Inflammation.
Cook SA; Schafer S
Annu Rev Med; 2020 Jan; 71():263-276. PubMed ID: 31986085
[TBL] [Abstract][Full Text] [Related]
5. Targeting the renin-angiotensin-aldosterone system in fibrosis.
AlQudah M; Hale TM; Czubryt MP
Matrix Biol; 2020 Sep; 91-92():92-108. PubMed ID: 32422329
[TBL] [Abstract][Full Text] [Related]
6. FOXO1/3: Potential suppressors of fibrosis.
Xin Z; Ma Z; Hu W; Jiang S; Yang Z; Li T; Chen F; Jia G; Yang Y
Ageing Res Rev; 2018 Jan; 41():42-52. PubMed ID: 29138094
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis.
Gasparini G; Cozzani E; Parodi A
Cytokine; 2020 Jan; 125():154799. PubMed ID: 31400638
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10-mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolism
Balaji S; Wang X; King A; Le LD; Bhattacharya SS; Moles CM; Butte MJ; de Jesus Perez VA; Liechty KW; Wight TN; Crombleholme TM; Bollyky PL; Keswani SG
FASEB J; 2017 Mar; 31(3):868-881. PubMed ID: 27903619
[TBL] [Abstract][Full Text] [Related]
9. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
Antic M; Distler JH; Distler O
Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
[TBL] [Abstract][Full Text] [Related]
10. Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family.
Sziksz E; Pap D; Lippai R; Béres NJ; Fekete A; Szabó AJ; Vannay Á
Mediators Inflamm; 2015; 2015():764641. PubMed ID: 26199463
[TBL] [Abstract][Full Text] [Related]
11. Therapy for fibrotic diseases: nearing the starting line.
Friedman SL; Sheppard D; Duffield JS; Violette S
Sci Transl Med; 2013 Jan; 5(167):167sr1. PubMed ID: 23303606
[TBL] [Abstract][Full Text] [Related]
12. ACKR2 limits skin fibrosis and hair loss through IFN-β.
Butenko S; Ben Jashar N; Sheffer T; Sabo E; Schif-Zuck S; Ariel A
FASEB J; 2021 Oct; 35(10):e21917. PubMed ID: 34533865
[TBL] [Abstract][Full Text] [Related]
13. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms.
Mi S; Li Z; Yang HZ; Liu H; Wang JP; Ma YG; Wang XX; Liu HZ; Sun W; Hu ZW
J Immunol; 2011 Sep; 187(6):3003-14. PubMed ID: 21841134
[TBL] [Abstract][Full Text] [Related]
14. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.
Frangogiannis NG
Mol Aspects Med; 2019 Feb; 65():70-99. PubMed ID: 30056242
[TBL] [Abstract][Full Text] [Related]
15. Notch in fibrosis and as a target of anti-fibrotic therapy.
Hu B; Phan SH
Pharmacol Res; 2016 Jun; 108():57-64. PubMed ID: 27107790
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis.
Bonniaud P; Margetts PJ; Ask K; Flanders K; Gauldie J; Kolb M
J Immunol; 2005 Oct; 175(8):5390-5. PubMed ID: 16210645
[TBL] [Abstract][Full Text] [Related]
17. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
[TBL] [Abstract][Full Text] [Related]
18. IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts.
Hong GH; Park SY; Kwon HS; Bang BR; Lee J; Kim SY; Pack CG; Kim S; Moon KA; Kim TB; Moon HB; Cho YS
Respir Res; 2018 Sep; 19(1):188. PubMed ID: 30257681
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid metabolism for fibrotic disorders.
Hwang S; Chung KW
Arch Pharm Res; 2021 Oct; 44(9-10):839-856. PubMed ID: 34664210
[TBL] [Abstract][Full Text] [Related]
20. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
Deng YL; Xiong XZ; Cheng NS
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
